Business Blockbuster - Helpng business to be more visible on Google

Business Daily Media


.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

The Hoffman Agency Taps Darren Burns as Asia Pacific President

Appointment builds on the independent consultancy's global ambitionsSILICON VALLEY, USA – Media OutReach Newswire – 17 November 2026 – The Hoffman Agency, an independent global communications cons...

KFC Thailand Breaks Creative Boundaries in 2026 with Bold Campaigns and Its First-Ever Original Manga "Dumb Luck"

Turning Cultural Insights, Pop Culture and Everyday Moments into Unexpected and Unforgettable Brand ExperiencesBANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 – KFC Thailand has bee...

From Black Friday to Christmas: Garvee Unveils a Holiday Gift Guide for the Year-End Shopping Season

ONTARIO, CANADA – Media OutReach Newswire – 17 November 2026 – With Black Friday, Cyber Monday and Christmas just around the corner, it's time to start thinking about gifts for family, friends and...

CHAGEE Grows to Eight Asia Pacific Markets with Brunei Entry; Unveils New Rooted in Tea Store Design

In the new design, tea is not just what CHAGEE serves, but what shapes the spaceSINGAPORE – Media OutReach Newswire – 17 November 2026 – CHAGEE is growing its family in Asia Pacific, opening its f...

Century-Old Guizhou Time-Honored Brand "Laishigang Sauce-Aroma Baijiu" Establishes Foothold in Hong Kong to Launch Southeast Asian and International Expansion Strategy

HONG KONG SAR – Media OutReach Newswire – 17 November 2026 – Guizhou Laishigang Liquor Co., Ltd. ("Laishigang Liquor"), a fifth-generation, century-old sauce-aroma baijiu producer certified as a ...

THE WORLD ENDS 2026 Connects Asia’s Creative and Design Networks to Unlock New Business Opportunities

International design platform brings together creative talent, industry partners and regional business networks, targeting 200 buyer–seller connections to foster business collaboration and cross-bo...

Ayara Kamala Reveals a Refreshed Vision for Wellness in Phuket

BANGKOK, THAILAND – Media OutReach Newswire – 17 November 2026 - Ayara Kamala Resort & Spa, an intimate haven nestled along Phuket's prestigious Kamala coastline, has officially unveiled its r...

China-Indonesia Cultural Industry Exchange Symposium Held in Jakarta

JAKARTA, INDONESIA – Media OutReach Newswire – 17 November 2026 – On the afternoon of November 13, the China-Indonesia Cultural Industry Exchange Symposium, co-hosted by the China Intercontinental...

Disney and Visa Announce Multi-Year Strategic Alliance Across Asia Pacific

The alliance spans Disney-branded card programmes, cardholder benefits and joint marketing initiatives across the regionHONG KONG SAR – Media OutReach Newswire – 17 November 2026 – The Walt Disney...

Galaxy Resort Presents: "Plácido Domingo & José Carreras: The Legends United Opera Gala"

Greater China and Macau's Only Performance Galaxy Rewards select members can enjoy privileged priority booking from 10 December 2026.Tickets go on public sale from 14 December 2026 CaptionMACAU SAR...

Why the secrecy around car insurance?

Every year, millions of Australians receive their car insurance renewal and promise themselves they’ll look at it properly later. Then life gets in ...

Australian workers spend almost an hour a day administering email

Research finds email filing, searching and rework consuming an estimated 58 minutes a day and potentially exposing organisations to millionsAustralian...

Customer Service Is Becoming Part of the Small Business Sales and Marketing Engine

For Customer Service Week, 5-9 October, Thryv is urging small businesses to look beyond generating  enquiries and examine what happens after a custome...

Gift Cards as the gateway to agentic payments

Prepaid and stored value gives consumers the trust and control to try AI shopping agents By Blackhawk Network VP Head of ANZ Kieran Nolan For deca...

Why Data Accumulation Without Governance Undermines Sustainability Goals

In July 2026, Group 2 entities, the second cohort of Australian businesses, began their first reporting period under the mandatory climate disclosur...

Permanent $20,000 Instant Asset Write-Off Gives Small Businesses Greater Planning Certainty

The Federal Government’s decision to permanently legislate the $20,000 instant asset write-off will give eligible small businesses greater certainty...